8-K Announcements
6Material company update
Dec 18, 2025·SEC
Material company update
Jul 24, 2025·SEC
Material company update
Dec 19, 2024·SEC
Greenwich LifeSciences, Inc.(GLSI)Earnings, Financials & Key Ratios
GLSI•NASDAQ
$18.33
Price updated Jun 25, 2026
AboutGreenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.Show more
- Revenue$0
- EBITDA-$19M-10.3%
- Net Income-$19M-11.2%
- EPS (Diluted)-1.43-18.2%
- ROE-895.3%-137.4%
GLSI Price & Volume
Greenwich LifeSciences, Inc. (GLSI) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Outpace Capital Liquidity
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Critical Liquidity and Dilution
"Greenwich LifeSciences remains a high-risk, pre-revenue biotechnology firm entirely dependent on the success of its FLAMINGO-01 clinical trial to justify its ongoing operations. The company's financial profile is characterized by an aggressive R&D-driven burn rate, which reached $5.2 million in 2026Q1, and a precarious liquidity position that may necessitate further dilutive financing. Investors should monitor the firm's ability to secure external capital, as the current trajectory of cumulative losses, reflected in a $92.8 million deficit in retained earnings, poses a significant threat to long-term shareholder value."
Verdict Logic
the company faces a critical liquidity crisis with a negative cash balance of $6.7 million and a persistent quarterly cash burn of $4.7 million that necessitates immediate and potentially dilutive capital raises.
GLSI Growth Metrics
Greenwich LifeSciences, Inc. (GLSI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-35.47%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-24.6%
Return on Capital
10 Years-160.89%
5 Years-190.23%
3 Years-298.04%
Last Year-418.46%
GLSI Recent Earnings
Greenwich LifeSciences, Inc. (GLSI) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)
Q3 2026Latest
Jun 3, 2026Metric
Actual
Est
EPS
$0.39-18.2%
$0.33
Rev
—
—
Q2 2026
Mar 31, 2026Metric
Actual
Est
EPS
$0.32+0.0%
$0.32
Rev
—
—
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$0.30+0.0%
$0.30
Rev
—
—
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.30-25.0%
$0.24
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q3 2026Latest | Jun 3, 2026 | $0.39vs $0.33-18.2% | — |
| Q2 2026 | Mar 31, 2026 | $0.32vs $0.32+0.0% | — |
| Q4 2025 | Nov 14, 2025 | $0.30vs $0.30+0.0% | — |
| Q3 2025 | Aug 14, 2025 | $0.30vs $0.24-25.0% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Greenwich LifeSciences, Inc. (GLSI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $18.33 | $269.05M | -12.82 | — | — | -895.3% | — | |
| $62.03 | $1.21B | -6.38 | -43.89% | -284.18% | -87% | — | |
| $72.64 | $8.62B | 28.37 | 37.55% | 23.13% | 126.27% | — | |
| $23.35 | $1.72B | 7.08 | 18.52% | 118.91% | 47.59% | — | |
| $53.23 | $13.52B | 19.15 | 6.98% | 35.08% | 40.21% | — | |
| $30.25 | $3.05B | -9.19 | -4.26% | -156.36% | -68.97% | — |
Compare GLSI vs Peers
Greenwich LifeSciences, Inc. (GLSI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
GLSI SEC Filings & Documents
Greenwich LifeSciences, Inc. (GLSI) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when GLSI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
GLSI Frequently Asked Questions
Greenwich LifeSciences, Inc. (GLSI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is GLSI profitable?
Greenwich LifeSciences, Inc. (GLSI) reported a net loss of $21.8M for fiscal year 2025.
Dividend & Returns
What is GLSI's return on equity?
Greenwich LifeSciences, Inc. (GLSI) has a return on equity (ROE) of -895.3%. Negative ROE indicates the company is unprofitable.
What is Greenwich LifeSciences, Inc.'s free cash flow?
Greenwich LifeSciences, Inc. (GLSI) had negative free cash flow of $12.8M in fiscal year 2025, likely due to heavy capital investments.